TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23379823

Group type: EXPERIMENTAL
Intervention: Human coronaviruses (HCoVs) detection in patients with AGE
Number of subjects: 260

Group type: COMPARATOR
Intervention: Human coronaviruses (HCoVs) detection in controls
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Detection of HCoVs in nasopharyngeal (NP) samples from patients with AGE
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Detection of HCoVs in stool samples from patients with AGE
Number of subjects: 260

Group type: COMPARATOR
Intervention: Detection of HCoVs in stool samples from controls
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Probability of HCoV detection in stool samples
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Probability of HCoV detection in stool and/or NP samples
Number of subjects: 260
Study: 23380277

Group type: EXPERIMENTAL
Intervention: Bafetinib 240 or 360 mg po, administered twice with a 12-hour interval
Number of subjects: 7
Study: 23380471

Group type: EXPERIMENTAL
Intervention: Average of 2782 ± 19 hours of daylight
Number of subjects: 235

Group type: COMPARATOR
Intervention: Average of 1681 ± 24 hours of daylight
Number of subjects: 235
Study: 23380715

Group type: EXPERIMENTAL
Intervention: Logistic regression model for predicting treatment resistance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naïve Bayes classifier, support vector machine, random forest model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline sociodemographic and clinical features
Number of subjects: 0
Study: 23382117

Group type: EXPERIMENTAL
Intervention: (111)In-labeled mature DCs with additional intradermal vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pretreatment with nonloaded, activated DCs, TNFα, or Imiquimod
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scintigraphy
Number of subjects: 0
Study: 23382400

Group type: EXPERIMENTAL
Intervention: Self-measured systolic blood pressure (SBP)
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Casual systolic blood pressure (SBP)
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Self-measured diastolic blood pressure (DBP)
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Casual diastolic blood pressure (DBP)
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Casual pulse pressure (PP)
Number of subjects: 1130
Study: 23382403

Group type: EXPERIMENTAL
Intervention: Low-sodium intervention (51.3 mmol sodium/day)
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: High-sodium intervention (307.8 mmol sodium/day)
Number of subjects: 1906
Study: 23382471

Group type: EXPERIMENTAL
Intervention: LN involvement
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Microscopic residual disease
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Overall stage III favorable-histology Wilms tumor
Number of subjects: 569
Study: 23382909

Group type: EXPERIMENTAL
Intervention: Belinostat
Number of subjects: 0
Study: 23383236

Group type: EXPERIMENTAL
Intervention: CLI patients
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: CAC from CLI patients
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: BM CD34(+) cell levels in CLI patients
Number of subjects: 101
Study: 23383749

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 243
Study: 23384490

Group type: EXPERIMENTAL
Intervention: Self-reported maximum walking distance (MWD)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Walking Impairment Questionnaire (WIQ)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Estimation of Ambulatory Capacity by History-Questionnaire (EACH-Q)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Incremental treadmill walking test
Number of subjects: 31

Group type: COMPARATOR
Intervention: 6-minute walk test
Number of subjects: 31
Study: 23384495

Group type: EXPERIMENTAL
Intervention: Medtronic Valiant Captivia stent graft
Number of subjects: 50
Study: 23384627

Group type: EXPERIMENTAL
Intervention: Methacholine challenge test (PC20 measurement)
Number of subjects: 88
Study: 23385153

Group type: EXPERIMENTAL
Intervention: HPV self-sampling with cervico-vaginal brush and iFTA elute cards
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: HPV positive women treated with cryotherapy after VIA triage
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Follow-up at 6 months after treatment
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Participant satisfaction with the screening program
Number of subjects: 632
Study: 23385197

Group type: EXPERIMENTAL
Intervention: Trabectedin (1.5 mg/m², intravenously over 24 hours, repeated every 21 days)
Number of subjects: 1895

Group type: EXPERIMENTAL
Intervention: Trabectedin
Number of subjects: 1895
Study: 23385985

Group type: EXPERIMENTAL
Intervention: Preexpanded perforator flaps (thoracodorsal artery perforator, intercostal artery perforator, circumflex scapular artery perforator)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Preexpanded perforator flaps
Number of subjects: 7
Study: 23386371

Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 12
Study: 23388195

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H1N1 pandemic vaccine
Number of subjects: 9143
Study: 23388350

Group type: EXPERIMENTAL
Intervention: Evidence-informed nursing management
Number of subjects: 424
Study: 23388405

Group type: EXPERIMENTAL
Intervention: 24-h systolic blood pressure variability (SBP)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: 24-h diastolic blood pressure variability (DBP)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: CV of awake DBP
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: CV and SD of 24-h and awake SBP/DBP
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: 24-h DBP
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: SD and CV for vascular damage
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: BPV (24-h, awake and sleep)
Number of subjects: 344
Study: 23388559

Group type: EXPERIMENTAL
Intervention: Proton therapy (54 Gy in 1.8 Gy per fraction)
Number of subjects: 23
Study: 23388612

Group type: EXPERIMENTAL
Intervention: Urine [TIMP-2]·[IGFBP7]
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Urine insulin-like growth factor-binding protein 7 (IGFBP7)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Tissue inhibitor of metalloproteinases-2 (TIMP-2)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Nine-variable clinical model with [TIMP-2]·[IGFBP7] added
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Sensitivity analyses with [TIMP-2]·[IGFBP7]
Number of subjects: 728
Study: 23390496

Group type: EXPERIMENTAL
Intervention: Telbivudine monotherapy (600 mg once-daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Telbivudine plus tenofovir (300 mg once-daily)
Number of subjects: 100
Study: 23391088

Group type: EXPERIMENTAL
Intervention: Assurant cobalt chromium balloon-expandable stent system
Number of subjects: 123
Study: 23391200

Group type: EXPERIMENTAL
Intervention: Pre-operative plasma GDF-15 levels
Number of subjects: 1458

Group type: EXPERIMENTAL
Intervention: Combined model of GDF-15 and additive EuroSCORE
Number of subjects: 1458

Group type: EXPERIMENTAL
Intervention: Presence of GDF-15 ≥1.8 ng/ml
Number of subjects: 1458

Group type: COMPARATOR
Intervention: Presence of NTproBNP (cutoff ≥2,000 pg/ml) or hsTNT (cutoff 14 pg/ml)
Number of subjects: 1458
Study: 23391248

Group type: EXPERIMENTAL
Intervention: Perioperative systemic polychemotherapy including cetuximab, cytoreductive surgery (CRS), and hyperthermic intraperitoneal chemotherapy (HIPEC) with intraperitoneal oxaliplatin
Number of subjects: 60
Study: 23391586

Group type: EXPERIMENTAL
Intervention: 18F-sodium fluoride (18F-NaF) for calcification
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 18F-fluorodeoxyglucose (18F-FDG) for inflammation
Number of subjects: 101

Group type: COMPARATOR
Intervention: Calcium scores
Number of subjects: 101
Study: 23391616

Group type: EXPERIMENTAL
Intervention: Topotecan (2.3 mg/m(2)/d) and bevacizumab (15 mg/kg) combination treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 50
Study: 23392444

Group type: EXPERIMENTAL
Intervention: 15° reverse Trendelenburg position
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 15° Trendelenburg position
Number of subjects: 51

Group type: COMPARATOR
Intervention: Comparison of reverse Trendelenburg to supine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Comparison of supine to Trendelenburg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Trendelenburg positioning
Number of subjects: 51
Study: 23392467

Group type: EXPERIMENTAL
Intervention: Atazanavir without tenofovir (300/100 mg during second trimester, 400/100 mg during third trimester, 300/100 mg postpartum)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Atazanavir with tenofovir (300/100 mg during second trimester, 400/100 mg during third trimester, 300/100 mg postpartum)
Number of subjects: 72
Study: 23392654

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (aspirin and clopidogrel)
Number of subjects: 565

Group type: COMPARATOR
Intervention: A-allele carriers of rs12041331
Number of subjects: 565

Group type: COMPARATOR
Intervention: A-allele carriers of rs12041331 in aspirin-treated INVEST-GENES patients
Number of subjects: 565
Study: 23393050

Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate
Number of subjects: 54
Study: 23393105

Group type: COMPARATOR
Intervention: Oral sodium bicarbonate (NaHCO3) at doses of 0.3, 0.6, and 1.0 mEq/kg per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral sodium bicarbonate (NaHCO3)
Number of subjects: 20
Study: 23393169

Group type: EXPERIMENTAL
Intervention: Boys with long CAG repeats (CAG ≥ 24)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Boys with short CAG repeats (CAG 17-20)
Number of subjects: 78
Study: 23393196

Group type: EXPERIMENTAL
Intervention: JX-594 treatment
Number of subjects: 0
Study: 23394586

Group type: EXPERIMENTAL
Intervention: Sutures
Number of subjects: 148

Group type: COMPARATOR
Intervention: Staples
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 148
Study: 23394629

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy with docetaxel 20 mg/m2 and oxaliplatin 50 mg/m2
Number of subjects: 24
Study: 23394838

Group type: EXPERIMENTAL
Intervention: Peroral endoscopic myotomy (POEM)
Number of subjects: 40
Study: 23394966

Group type: EXPERIMENTAL
Intervention: Parental restriction and family pressure to be thin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Media pressure
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Appearance orientation and preoccupation with becoming overweight
Number of subjects: 90
Study: 23395076

Group type: EXPERIMENTAL
Intervention: iFR (instantaneous wave-free ratio)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: iFR (instantaneous wave-free ratio) at rest
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: iFR (instantaneous wave-free ratio) with hyperemia
Number of subjects: 206

Group type: COMPARATOR
Intervention: FFR (fractional flow reserve)
Number of subjects: 206
Study: 23395934

Group type: EXPERIMENTAL
Intervention: Increasing galectin-3 levels over time (from low to high category)
Number of subjects: 1653

Group type: EXPERIMENTAL
Intervention: Galectin-3 increase >15% between measurements
Number of subjects: 1653

Group type: COMPARATOR
Intervention: Stable or decreasing galectin-3 levels
Number of subjects: 1653
Study: 23396491

Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) nicorandil 2 mg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Intravenous (i.v.) adenosine infusion (140 μg/kg/min)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Intracoronary (IC) adenosine
Number of subjects: 210

Group type: COMPARATOR
Intervention: Intravenous (i.v.) adenosine
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) nicorandil
Number of subjects: 210
Study: 23396494

Group type: EXPERIMENTAL
Intervention: Laparoscopic distal gastrectomy
Number of subjects: 1415

Group type: COMPARATOR
Intervention: Open distal gastrectomy
Number of subjects: 1415
Study: 23396557

Group type: EXPERIMENTAL
Intervention: Routine iron (n=2184; 60 mg ferrous sulfate plus 400 μg of folic acid daily throughout pregnancy)
Number of subjects: 4326

Group type: COMPARATOR
Intervention: Selective iron (n=2142; screening and treatment for anaemia and daily intake of 1 mg of folic acid)
Number of subjects: 4326
Study: 23398615

Group type: EXPERIMENTAL
Intervention: Grandmothers, Aunts, Female Family Friends
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Grandmothers, Fathers
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Maternal Parenting
Number of subjects: 159
Study: 23398640

Group type: EXPERIMENTAL
Intervention: N8-GP (25, 50, or 75 U kg(-1))
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: N8-GP (50 U kg(-1))
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: N8-GP
Number of subjects: 26
Study: 23398660

Group type: EXPERIMENTAL
Intervention: Video capsule endoscopy (Pillcam Eso2; Given Imaging)
Number of subjects: 25
Study: 23398686

Group type: EXPERIMENTAL
Intervention: Prudent dietary pattern (high intakes of vegetables, fruits, whole grain products)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Western dietary pattern (high intakes of refined grain products, desserts, sweets, and processed meats)
Number of subjects: 210
Study: 23399938

Group type: EXPERIMENTAL
Intervention: Pancreatic stone protein
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Procalcitonin
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Interleukin-6
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: White blood cells (WBCs)
Number of subjects: 91
Study: 23400739

Group type: EXPERIMENTAL
Intervention: Dovitinib (5-days-on/2-days-off intermittent dosing schedule)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dovitinib (continuous daily dosing schedule)
Number of subjects: 0
Study: 23401019

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation
Number of subjects: 11
Study: 23401248

Group type: EXPERIMENTAL
Intervention: Uric acid (UA) levels
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Leptin and adiponectin (in adults only)
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Nuchal and visceral fat measurements
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Carotid intima media thickness (IMT)
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS) criteria
Number of subjects: 709
Study: 23401274

Group type: EXPERIMENTAL
Intervention: MMP9 upregulation in bone PCR
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MMP9 upregulation in mucosa PCR
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: MMP2 and TIMP1 regulation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Steroid treatment
Number of subjects: 35
Study: 23401442

Group type: EXPERIMENTAL
Intervention: R-BAC (rituximab 375 mg/m(2) IV on day 1, bendamustine 70 mg/m(2) IV on days 2 and 3, cytarabine 800 mg/m(2) IV on days 2 to 4) every 28 days for four to six cycles
Number of subjects: 40
Study: 23403011

Group type: EXPERIMENTAL
Intervention: Thienopyridines
Number of subjects: 516

Group type: COMPARATOR
Intervention: Control (no thienopyridines)
Number of subjects: 516
Study: 23403253

Group type: EXPERIMENTAL
Intervention: Oral ketamine at 0.25-1 mg/kg/dose for 14 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral ketamine at 1.5 mg/kg/dose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral ketamine at 1 mg/kg/dose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral ketamine at 0.25-1 mg/kg/dose
Number of subjects: 12
Study: 23403322

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (24 courses)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Plasma-derived factor VII
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Frequent courses (three times weekly, n=23)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Infrequent courses (≤ 2 times weekly, n=15)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Overall prophylaxis
Number of subjects: 34
Study: 23404722

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control (no statins)
Number of subjects: 328
Study: 23406027

Group type: EXPERIMENTAL
Intervention: Selumetinib (75 mg twice daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Radioiodine therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Selumetinib
Number of subjects: 20
Study: 23406163

Group type: EXPERIMENTAL
Intervention: RESMENA diet
Number of subjects: 96

Group type: COMPARATOR
Intervention: AHA dietary pattern
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Dietary TAC
Number of subjects: 96
Study: 23406538

Group type: EXPERIMENTAL
Intervention: High PAPP-A levels (Q3 and Q4)
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Calprotectin in upper quartile (Q4)
Number of subjects: 871
Study: 23406600

Group type: EXPERIMENTAL
Intervention: Nonallergic rhinitis (NAR)
Number of subjects: 175
Study: 23406688

Group type: COMPARATOR
Intervention: South Asian ethnicity
Number of subjects: 111555

Group type: COMPARATOR
Intervention: Diabetes in South Asians
Number of subjects: 111555

Group type: COMPARATOR
Intervention: South Asian ethnicity among diabetics, older people, and those in high deprivation areas
Number of subjects: 111555
Study: 23406700

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (ET) for 8 weeks (~180 min/wk at 40-55% VO2PeakR)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (ET)
Number of subjects: 11
Study: 23407305

Group type: EXPERIMENTAL
Intervention: trans-palmitoleate concentrations
Number of subjects: 2617
Study: 23408352

Group type: EXPERIMENTAL
Intervention: Circulating methylated SEPT9 DNA (mSEPT9)
Number of subjects: 7941

Group type: COMPARATOR
Intervention: Control group (subjects without CRC)
Number of subjects: 7941
Study: 23409033

Group type: EXPERIMENTAL
Intervention: Circulating progranulin levels in subjects with metabolic syndrome
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Circulating progranulin levels
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Serum progranulin levels
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: CTRP3 concentrations
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: IL-6 and triglyceride levels
Number of subjects: 127
Study: 23410147

Group type: EXPERIMENTAL
Intervention: Triple therapy for chronic hepatitis C, specific details not available.
Number of subjects: 0
Study: 23410543

Group type: EXPERIMENTAL
Intervention: Mental stress-induced ischemia
Number of subjects: 310

Group type: COMPARATOR
Intervention: Exercise-induced ischemia
Number of subjects: 310
Study: 23411383

Group type: EXPERIMENTAL
Intervention: Second-generation EGFR TKIs (e.g., afatinib, dacomitinib, XL647, AP26113, CO-1686)
Number of subjects: 0

Group type: COMPARATOR
Intervention: First-generation EGFR TKIs (e.g., erlotinib, gefitinib)
Number of subjects: 0
Study: 23411385

Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active Treatment
Number of subjects: 0
Study: 23411428

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (20,000 IU weekly for 12-13 weeks)
Number of subjects: 30
Study: 23414587

Group type: EXPERIMENTAL
Intervention: MEK162 45 mg for NRAS-mutated melanoma
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: MEK162 45 mg for BRAF-mutated melanoma
Number of subjects: 71
Study: 23415622

Group type: EXPERIMENTAL
Intervention: LDL-P > LDL-C subgroup (n = 375)
Number of subjects: 2384

Group type: EXPERIMENTAL
Intervention: LDL-P < LDL-C subgroup (n = 428)
Number of subjects: 2384

Group type: COMPARATOR
Intervention: Concordant subgroup (LDL-P ≅ LDL-C)
Number of subjects: 2384
Study: 23415641

Group type: EXPERIMENTAL
Intervention: BRAF inhibitors
Number of subjects: 0
Study: 23416208

Group type: EXPERIMENTAL
Intervention: Detection of pathogens by PCR
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Pathogen identification
Number of subjects: 1065
Study: 23416644

Group type: EXPERIMENTAL
Intervention: PCA3 score cutoff of 25
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: PCA3 score less than 25
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Adding PCA3 score to logistic regression model
Number of subjects: 466
Study: 23416850

Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning regimen (cyclophosphamide 50 mg/kg, fludarabine 150 mg/m(2), thiotepa 10 mg/kg, and 400 cGy total body irradiation with cyclosporine-A/mycophenolate mofetil immunosuppression)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning regimen
Number of subjects: 30
Study: 23416852

Group type: EXPERIMENTAL
Intervention: Myeloablative sibling MRD HSCT
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Reduced-intensity parental haploidentical donor HSCT
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both MRD and haploidentical donor HSCT
Number of subjects: 22
Study: 23417027

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activin A-neutralizing antibody
Number of subjects: 0
Study: 23417207

Group type: EXPERIMENTAL
Intervention: Family Satisfaction in the ICU (FS-ICU) questionnaire; Quantitative analysis with a summary score of 78.3 ± 14.3 on a scale of 0 to 100.
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of open-ended questions; Themes identified for improvement: patient agitation, clarity and completeness of information, emotional support, respect and compassion towards families.
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Waiting room, ICU atmosphere, and amenities for visiting relatives; Not explicitly quantified.
Number of subjects: 215
Study: 23417339

Group type: EXPERIMENTAL
Intervention: POAG patients
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: OHT patients
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Correlation of flicker response to intraocular pressure (IOP)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Correlation of flicker response to level of glaucomatous damage
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Correlation of flicker response between superior and inferior vessels of the same eye
Number of subjects: 146